XTL Biopharmaceuticals Ltd.

XTL BIOPHARMACEUTICALS LTD is an intellectual property-based company focused on developing, managing, and commercializing intellectual property. The company operates in the biotech sector through its subsidiary, Psyga Bio, and in the biopharmaceutical industry. In the biopharmaceutical industry, XTL BIOPHARMACEUTICALS LTD holds a license from Yeda Research and Development Company Ltd. for hCDR1, a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). In March 2025, XTL BIOPHARMACEUTICALS LTD entered into an Exclusive Sublicense Agreement with Biossil Inc., a Canadian company. Under this agreement, XTL BIOPHARMACEUTICALS LTD granted Biossil a royalty-free, exclusive, worldwide perpetual sublicense, with multi-tier sublicensing rights, for its synthetic peptide, hCDR1. This sublicense includes related patent applications, provisional applications, resulting patents, and all know-how, including clinical and pre-clinical data related to the product called Edratide, as well as trademarks, trade names, logos, and labeling necessary for its research, development, manufacture, and commercialization. Yeda was informed and agreed to this agreement. In April 2026, XTL BIOPHARMACEUTICALS LTD acquired Psyga Bio Ltd., an Israeli company. Psyga Bio is an advanced biotechnology company researching, developing, and commercializing proprietary products from psychedelic and functional mushrooms, including therapeutic candidates, microdosing solutions, and wellness formulations. Psyga Bio operates a licensed, GMP-ready pharmaceutical manufacturing facility for the cultivation, extraction, isolation, formulation, and production of pharmaceutical-grade botanical and synthetic psilocybin, Ibogaine, and other psychedelic active pharmaceutical ingredients (APIs), adhering to international pharmaceutical manufacturing standards.